Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2008-10-01
2011-11-15
Afremova, Vera (Department: 1653)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C424S009100, C424S236100, C424S247100
Reexamination Certificate
active
08057807
ABSTRACT:
The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
REFERENCES:
patent: 4932936 (1990-06-01), Dykstra et al.
patent: 5183462 (1993-02-01), Borodic
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5674205 (1997-10-01), Pasricha et al.
patent: 5837265 (1998-11-01), Montal et al.
patent: 5919665 (1999-07-01), Williams
patent: 5939070 (1999-08-01), Johnson et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6365164 (2002-04-01), Schmidt
patent: 6383509 (2002-05-01), Donovan et al.
patent: 6506399 (2003-01-01), Donovan
patent: 6585993 (2003-07-01), Donovan et al.
patent: 6667041 (2003-12-01), Schmidt
patent: 6939852 (2005-09-01), Graham
patent: 7001602 (2006-02-01), Schmidt
patent: 7153514 (2006-12-01), Schmidt
patent: 7429387 (2008-09-01), Schmidt
patent: 7449192 (2008-11-01), Schmidt
patent: 7455845 (2008-11-01), Allen et al.
patent: 7470431 (2008-12-01), Schmidt
patent: 2005/0048084 (2005-03-01), Schmidt
patent: 2005/0112147 (2005-05-01), Schmidt
patent: 2005/0175636 (2005-08-01), Donovan
patent: 2008/0177248 (2008-07-01), Schmidt
patent: 2009/0004312 (2009-01-01), Schmidt
patent: 2009/0068227 (2009-03-01), Schmidt
patent: 2005 234633 (2007-04-01), None
patent: 6-183975 (1994-07-01), None
patent: 8-511537 (1996-12-01), None
patent: WO 95/05842 (1995-03-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 99/03483 (1999-01-01), None
“Treatment How IS Prostate Cancer Treated?”, American Foundation for Urologic Disease, available at http://www.afud.org/conditions/pctreat.html, printed Aug. 5, 2003, pp. 1-2.
“Continence Management”; The Prostate Cancer Charity, available at http://www.prostate-cancer.org.uk/learn/prostateCancer/livingWith/continenceManagement.asp, printed Aug. 8, 2003, pp. 1-6.
“Incontinence & the Prostate”, from Morganstern Urology Clinic & Men's Health Center, Phoenix5, available at http://www.phoenix5.org/Basics/treatsides/incontinence/incontMorganstern.html, printed Aug. 5, 2003, pp. 1-11.
“Prostate Cancer (PDQ®): Treatment”; National Cancer Institute, available at http://www.cancer.gov/cancerinfo/pdq/treatment/prostate, date last modified Jul. 17, 2003, pp. 1-11.
“Prostate Cancer: prostate cancer transrectal biopsies”; available at http://216.239.41.104/search?q=cache:RUEZIFhOxiAJ:www.listure.com/prostate-cancer/pro..., printed Aug. 20, 2003, pp. 1-9.
“Prostate Cancer: Tumor Grading”; University of Pittsburgh Medical Center Cancer Centers, available at http://www.upmccancercenters.com/cancer/prostate/gradingsystems.html, printed Aug. 11, 2003, pp. 1-2.
“Prostate Cancer: What are the Treatment Options?”; NSW Health, publication No. BHC-6055, available at http://www.mhcs.health.nsw.gov.au/health-public-affairs/mhcs/publications/6055.html, publication date Jan. 4, 2002, pp. 1-2.
“Prostate Gland and Urinary Problems”; Better Health Channel, available at http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Prostate—gland—and—urinary—p..., article publication date Oct. 10, 2001, pp. 1-4.
“Questions and Answers About the Prostate-Specific Antigen (PSA) Test”; National Cancer Institute, available at http://cis.nci.nih.gov/fact/5—29.htm, date reviewed Jan. 11, 2001, pp. 1-5.
“Symptoms & Treatments Bladder Management in Multiple Sclerosis”; Multiple Sclerosis International Federation, available at http://www.msif.org/en/symptoms—treatments/ms—by—topic/continence/articles/bladder—man... printed Sep. 30, 2003, pp. 1-6.
“The Side Effects of Treatment”; Varian Medical System, available at http://www.varian.com/pti/cty102c.html, printed Aug. 5, 2003, pp. 1-2.
“Treating Prostate Disease”; The Cleveland Clinic, available at http://www.clevelandclinic.org/quality/08-12/08-12c.htm, dated Jan. 28, 1999, pp. 1-3.
“Understanding Gleason Grading”; Phoenix5, available at http://www.phoenix5.org/Infolink/GleasonGrading.html, last revised May 14, 1997, pp. 1-6.
“Western Multiple Sclerosis Center's Glossary”; UW Medicine, available at http://216.239.53.104/search?q=cache:tbApZaM3—5kJ:www.washington.edu/medicine/patien..., printed Sep. 30, 2003, pp. 1-15.
1996 MIMS Annual, Australian Edition. p. 5-372 to 5-373.
Amarenco, “Pour la practiqe” Lae Revue du Praticien (Paris) 1995 45:343-45.
Amarenco, “Evaluation et Traitment des Dysfoctionnements Vesico-Sphincteriens Neurogenes” Annales d'Urologie 27 (1993) pp. 313-320.
Araki et al. Detrusor-Sphincter Dyssynergia with Special Reference to its Diagnosis and Treatment, J. Saitama Med. School, 1992, 23-27, vol. 19, Department of Urology, Saitama Medical School, Moroyama, Iruma-gun, Saitama, Japan (partial translation).
Bardsley; “The Neurogenic Bladder”; Nursing Standard, vol. 14, No. 22, accepted Jan. 7, 2000, pp. 39-41.
Beleggia et al., “L'impiego della tossina botulinica tipo A nel trattamento della dissinergia detrusore sfintere” Arch. It. Urol., LXIX, (S.1): 61-63, 1997 (English Abstract).
Burnstein et al.; “Prostatitis: A Difficult Diagnosis”; available at http://216.239.41.104/search?q=cache:BP KHOclaaYAJ:wwww.jaybursteinmd.com/uro/jaydbur..., printed Aug. 20, 2003, pp. 1-3.
“Bladder Problems Explained”, Pfizer, Ltd., available at http://www.bladderzone.com/info/bladder—expl.htm, printed Oct. 20, 2005 (Copyright 2003), pp. 1-2.
Borodic and Pearce, “New Concepts in Botulinum Toxin Therapy”, Drug Safety 11 (1994), pp. 145 to 152.
Boyd, et al., “Transient urinary incontinence after botulinum A toxin” Lancet 1996 348:481-82.
Bruschini et al., “Neurologic control of prostatic secretion in the dog.” Invest. Urol., 15(4):288-290 (1978).
Bulau, Itherapeutische Perspektiven mit Botulinumtoxin Type A, Neurologie and Rehabilitation, Band 3, Heft 1 (1997) pp. 55-56. (including translation).
Burnstein et al.; “Prostatitis: A Difficult Diagnosis”; DeKalb Clinic Urology; (at least as early as Aug. 20, 2003); 3 pp.
Carl, Stefan, Affidavit, Sep. 26, 2006, pp. 1-3.
Chancellor et al., “Successful Use of Bladder Botulinum Toxin Injection to Treat Refractory Overactive Bladder” J Urol Apr. 2003;169 (Supp 4):351.
Crawford; “Prostate Cancer”; Best Doctors; (Jun. 7, 2000); 6 pp.
DasGupta et al., “The management of femal voiding dysfunction: Fowler's syndrome—a contemporary update” Urogynaecology 2003, 13:293-299.
Doggweiler et al. “Botox-Induced Prostatic Involution” The Prostate, vol. 37, No. 1, pp. 44-50 (1998).
Downie et al., “Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats.” J. Pharmacol. Exp. Ther., 246(1):352-358 (1988).
Dykstra et al., “Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study” Arch. Phys. Med. Rehabil., 71:24-26 (1990).
Dykstra et al.; “Effects of Botulinum a Toxin on Detrusor-Sphincter Dyssynergia in Spinal Cord Injury Patients”; J. Urology; 139:919-922; (May 1988).
Entry for “benigne Prostatahyperblasie” in Pschyrembel, klinisches Wörterbuch (257. Auflage, 1994). 2 pages.
Epstein;“Gleason Score 2-4 Adenocarcinoma of the Prostate on Needle Biopsy”; American Journal of Surgical Pathology; (2000) vol. 24(4); pp. 477-478.
Fowler C J et al: “Myotonic-Like EMG Activity of the Urethral Sphincter in Women With Urinary Retention and the Use of Botulinum Toxin to Treat This Disorder” Neurophysiologie Clinique, vol. 20, no. Suppl, 1990, p. 19S, XP009058311 & 5TH European Congress of Clinical Neurophysiology, Paris, France, Sep. 9-12, 1990. N
Afremova Vera
Condino Debra
Gibson Hal
The Regents of the University of Colorado, a body corporate
LandOfFree
Use of botulinum toxin therapy for treatment of recalcitrant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of botulinum toxin therapy for treatment of recalcitrant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of botulinum toxin therapy for treatment of recalcitrant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272025